Glucocorticoids in nephrology I: pharmacology and side effects
DOI:
https://doi.org/10.6016/ZdravVestn.1236Keywords:
synthetic glucocorticoids, hypothalamo-hypophyseal hormonal axis, immunosuppresion, glucocorticoid receptor, genomic effects, non-genomic-effectsAbstract
Glucocorticoids have been used in clinical medicine since 1940s. Despite the time-long use they are still a subject of active ongoing research. We describe the mode of action, pharmacology and side effects to enable proper prescription of these drugs. Glucocorticoids exert genomic and non-genomic effects, the latter become important at higher doses. The nomenclature of dosage ranges and the principles of dosage adjustments are given. Glucocortioid use is associated with frequent and important side effects in numerous organ systems. Prophylactic treatments for osteoporosis and infections are described. The suppression of hypothalamic-hypophyseal hormonal axis determines the need for gradual glucocorticoid withdrawal and supplementation after discontinuation. Finally, glucocorticoid withdrawal syndrome is described.
Downloads
References
Raju TN. The Nobel chronicles. 1950: Edward Calvin Kendall (1886-1972); Philip Showalter Hench (1896-1965); and Tadeus Reichstein (1897-1996). Lancet. 1999; 353: 1370.
Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med. 1950; 85: 545–666.
Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol. 2011; 29(5 Suppl 68): S5–12.
Arneil GC. Treatment of nephrosis with prednisolone. Lancet. 1956; 270: 409–11.
Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev. 2014; 13: 206–14.
Besedovsky H, del Rey A, Sorkin E, Dinarello C. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 1986; 233: 652–4.
Jacobs JWG, Bijlsma JWJ. Glucocorticoid therapy. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR, editors. Kelley’s textbook of Rheumatology. Philadelphia: Elsevier Inc; 2013. p. 894–916.
Biddie SC, Conway-Campbell BL, Lightman SL. Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatol. 2012; 51: 403–12.
Stavreva DA, Wiench M, John S, et al. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol. 2009; 11: 1093–102.
Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis. 2003; 62: 593–6.
Arvidson NG, Gudbjörnsson B, Larsson A, Hällgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997; 56: 27–31.
Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008; 371: 205–14.
Kirwan J, Power L. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheunatol. 2007; 19: 233–7.
John S, Sabo PJ, Thurman RE, et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet. 2011; 43: 264–8.
Buttgereit F, Saag KG, Cutolo M, da Silva J a. P, Bijlsma JWJ. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005; 34: 14–21.
Strehl C, Spies CM, Buttgereit F. Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol. 2011; 29(5 Suppl 68): S13–8.
Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues. Eur J Endocrinol. 2001; 144: 87–97.
Buttgereit F, da Silva J a P, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002; 61: 718–22.
McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J. 1983; 286: 923–5.
Tritos NA, Biller BMK. Advances in Medical Therapies for Cushing’s Syndrome. Discov Med. 2012; 13: 171–9.
Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review. Intensive Care Med. 2011; 37: 901–10.
Flynn G, Shehabi Y. Pro/con debate: Is etomidate safe in hemodynamically unstable critically ill patients? Crit Care. 2012; 16: 227.
Colburn NT. Corticosteroids. In: Colburn NT, editor. Review of Rheumatology. London: Springer London; 2012. p. 493–506.
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365: 62–70.
Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos int. 2007; 18: 1319–28.
Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos int. 2008; 19: 385–97.
Hansen KE, Wilson HA, Zapalowski C, Fink H a, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Min Res. 2011; 26: 1989–96.
Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Min Res. 1999; 14: 1061–6.
Pereira RMR, Freire de Carvalho J. Glucocorticoid-induced myopathy. Jt Bone Spine. 2011; 78: 41–4.
Kocjan T, Preželj J, Pfeifer M, Jensterle Sever M, Čokolič M, Zavratnik A. Smernice za odkrivanje in zdravljenje osteoporoze. Zdr Vestn. 2013; 82: 207–17.
Gordon PL, Frassetto L a. Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis. 2010; 55: 941–56.
Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74: 1385–93.
Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028–39.
Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010; 62: 1515–26.
Chrousos GP, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med. 1998; 129: 229–40.
Luton JP, Thieblot P, Valcke JC, Mahoudeau JA, Bricaire H. Reversible gonadotropin deficiency in male Cushing’s disease. J Clin Endocrinol Metab. 1977; 45: 488–95.
Kwon S, Hermayer KL. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013; 345: 274–7.
Van der Goes MC, Jacobs JWG, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010; 69: 1913–9.
Whitworth J a, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Heal Risk Manag. 2005; 1: 291–9.
Ettinger WH, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab. 1988; 67: 425–8.
Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arter Thromb Vasc Biol. 2007; 27: 661–70.
McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372: 224–33.
Quaschning T, Mainka T, Nauck M, Rump LC, Wanner C, Krämer-Guth A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl. 1999; 71: S235–7.
Hoes JN, Jacobs JWG, Verstappen SMM, Bijlsma JWJ, Van der Heijden GJMG. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009; 68: 1833–8.
Vanrenterghem YFC, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008; 85: 209–16.
Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation. 2010; 89: 1–14.
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008; 248: 564–77.
Arnol M, de Mattos AM, Chung JS, Prather JC, Mittalhenkle A, Norman DJ. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation. 2008; 86: 1844–8.
Opelz G, Döhler B, Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transpl. 2005; 5: 720–8.
Rike AH, Mogilishetty G, Alloway RR, et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transpl. 2008; 22: 229–35.
Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci. 2009; 1179: 41–55.
Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012; 53: 103–15.
Opelz G, Döhler B. Association between steroid dosage and death with a functioning graft after kidney transplantation. Am J Transpl. 2013; 13: 2096–105.
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide M-V, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009; 11: R109.
Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013; 72: 1905–13.
Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011; 17: 2340–9.
Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther. 2009; 11: 253.
Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect Dis. 2004; 4: 42.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Inter Suppl. 2012; 2: 139–274.
Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013; 32: 1071–3.
Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009; 68: 1119–24.
Sarwal MM, Ettenger RB, Dharnidharka V, et al. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transpl. 2012; 12: 2719–29.
Salassa RM, Bennet WA, Keating FR, Sprague RG. Postoperative adrenal cortical insufficiency; occurrence in patients previously treated with cortisone. J Am Med Assoc. 1953; 152: 1509–15.
Dinsen S, Baslund B, Klose M, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Int Med. 2013; 24: 714–20.
Schuetz P, Christ-Crain M, Schild U, et al. Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med. 2008; 8: 1.
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000; 355: 542–5.
Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrionol. 2009; 160: 719–29.
Kocjan T. Odpoved skorje nadledvičnih žlez. In: Kocjan T, editor. Razširjeni povzetki predavanj / 2. šola iz endokrinologije, Portorož 10. in 11. maj 2013. Ljubljana: Slovensko osteološko društvo; 2013. p. 37–44.
Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002; 31: 751–78.
Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003; 24: 523–38.
Bhattacharyya a, Kaushal K, Tymms DJ, Davis JRE. Steroid withdrawal syndrome after successful treatment of Cushing’s syndrome: a reminder. Eur J Endocrionol. 2005; 153: 207–10.
Fardet L, Nazareth I, Whitaker HJ, Petersen I. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013; 74: e281–6.
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
